Login to Your Account

Federal Circuit Again Upholds Myriad's BRCA Gene Claims

By Mari Serebrov
Washington Editor

Friday, August 17, 2012
Isolated DNA is patent-eligible because it is a "non-naturally occurring composition of matter," so said an appellate court in determining, once again, the validity of Myriad Genetics Inc.'s claims for its BRACAnalysis breast cancer gene test.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription